AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$GH

Tariq Musa sold $20K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $175.00 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Sep 17, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting no immediate price pressure.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this minor sale.

Relevance 2/10Novelty 4/10Timing: post‑market 2026-09-16

Background

Form 4 filings disclose insider transactions; directors often use 10b5‑1 plans to avoid timing concerns.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Director Tariq Musa sold 116 shares of Guardant Health for $20.3K on 2026-09-16 via a 10b5‑1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to market cap and disclosed via a pre‑arranged plan, indicating no urgent market signal.

Market effects

Sector

None; insider sale does not affect broader biotech sector.

Regional

None; limited to Guardant Health shareholders.

Global

None; no global market effect.

Counterpoint

What could challenge this read

Some investors may view any insider selling as a negative signal, but the small amount and pre‑arranged plan mitigate concern.

Key entities

  • Company
    Guardant Health, Inc.

    US‑listed liquid biopsy company (NASDAQ: GH).

  • Individual
    Tariq Musa

    Director of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

OCT 20
$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

insidermonkey.com3 min
OCT 9
$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.

onclive.com6 min